The
slide to be stained for
Bcl-2 comprised:
1. Tonsil, fixed for 24 h, 2. Appendix, 3. Tonsil, fixed for 48 h,
4. Follicular lymphoma, grade II, 5. Follicular lymphoma, grade III
All tissues were fixed in 10 % neutral buffered formalin.
Criteria for assessing a Bcl-2 staining as optimal included:
- A moderate to strong predominantly
cytoplasmic staining of virtually all the peripheral B- and
T-cells in the tonsils and appendix.
- An at least weak cytoplasmic staining of
the basal squamous epithelial cells of the tonsil and of the
basal epithelial cells in the appendix.
- An at least weak to moderate staining of
virtually all the neoplastic cells in the two follicular
lymphomas.
- No staining reaction in the germinal
centre B-cells.
155 laboratories participated in this assessment. 82 % achieved a
sufficient mark. In table 1 the antibodies (Abs) used and marks are
summarized.
Table 1.
Abs and
assessment marks
for Bcl-2, run 28
|
Concentrated Abs |
N |
Vendor |
Optimal |
Good |
Borderl. |
Poor |
Suff.1 |
Suff. OPS2 |
|
mAb
clone 124 |
98
1 |
Dako
Cell Marque |
49 |
35 |
15 |
0 |
85 % |
86 % |
|
mAb clone
100/D5 |
5
1
1
1 |
NeoMarkers
Biocare
Immunologic
Master Diagnostica |
2 |
5 |
1 |
0 |
89 % |
100 % |
mAb clone
bcl-2/100/D5 |
5 |
Novocastra |
3 |
1 |
0 |
1 |
80 % |
- |
|
mAb clone 100 |
2 |
BioGenex |
2 |
0 |
0 |
0 |
- |
- |
|
mAb clone 3.1 |
2 |
Novocastra |
0 |
2 |
0 |
0 |
- |
- |
|
mAb clone
Bcl-2-100 |
1 |
Zymed |
0 |
0 |
1 |
0 |
- |
- |
|
mAb clone 8C8 |
1 |
NeoMarkers |
0 |
1 |
0 |
0 |
- |
- |
|
Ready-To-Use Abs |
|
|
|
|
|
|
|
|
|
mAb clone 124,
IR614 |
14 |
Dako |
10 |
4 |
0 |
0 |
100 % |
100 % |
mAb clone
124, 760-4240 |
18 |
Ventana/Cell
Marque |
0 |
8 |
9 |
1 |
44 % |
- |
mAb clone
124, MON-RTU1011 |
1 |
Monosan |
0 |
0 |
1 |
0 |
- |
- |
|
mAb clone bcl-2/ 100/D5, PA0117 |
2 |
Leica |
2 |
0 |
0 |
0 |
- |
- |
mAb
clone
100/D5, PM003 |
1 |
Biocare |
0 |
1 |
0 |
0 |
- |
- |
mAb
clone
100/D5, 760-2693 |
1 |
Ventana |
0 |
1 |
0 |
0 |
- |
- |
|
Total |
155 |
|
68 |
58 |
27 |
2 |
- |
- |
|
Proportion |
|
|
44 % |
38 % |
17 % |
1 % |
82 % |
- |
1) Proportion of sufficient stains
(optimal or good), 2) Proportion of sufficient stains with optimal
protocol settings only, see below.
The following central protocol parameters were used to obtain an optimal
staining:
Concentrated Abs
mAb clone 124: The protocols giving an optimal result were
all based on heat induced epitope retrieval (HIER) in one of the
following buffers: Tris-EDTA/EGTA pH 9 (13/22)*, Target Retrieval Solution pH 9
(EnVision FLEX TRS high pH, Dako)(20/28), Target Retrieval Solution
pH 6.1 (S1699, Dako)(1/1), Cell Conditioning 1 (BenchMark, Ventana)
(4/22), Bond Epitope Retrieval Solution 2 (Bond, Leica) (1/4), Bond
Epitope Retrieval Solution 1 (Bond, Leica) (1/1), EDTA/EGTA pH8
(2/3) or Citrate pH 6 (7/14). The mAb was
typically diluted in the range of 1:10– 1:400 depending on the total
sensitivity of the protocol employed. Using these protocol settings
77 out of 90 (86 %) laboratories produced a sufficient staining
(optimal or good).
* (number of optimal results/number of
laboratories using this buffer)
mAb clone 100/D5: The protocols giving an optimal result were
both based on heat induced epitope retrieval (HIER) in one of the
following buffers: EDTA/EGTA pH 8 (1/1) or Citrate pH 6 (1/2).
The mAb was typically diluted in the range of 1:50– 1:100 depending
on the total sensitivity of the protocol employed. Using these
protocol settings both of 2 laboratories produced an
optimal staining.
mAb clone bcl-2/100/D5: The protocols giving an optimal
result were both based on heat induced epitope retrieval (HIER)
using Tris-EDTA/EGTA pH 9 (3/3) as the retrieval buffer. The mAb was
typically diluted in the range of 1:20– 1:40 depending on the total
sensitivity of the protocol employed. Using these protocol settings
both of 2 laboratories produced an optimal staining.
mAb clone 100: The protocols giving an optimal result were
both based on heat induced epitope retrieval (HIER) in one of the
following buffers: Tris-EDTA/EGTA pH 9 (1/1) or Bond Epitope Retrieval Solution 2
(Bond, Leica) (1/1). The mAb was typically
diluted in the range of 1:200– 1:1.200 depending on the total
sensitivity of the protocol employed. Using these protocol settings
both of 2 laboratories produced an optimal staining.
Ready-To-Use Abs
mAb clone 124 (prod. no IR614, Dako): The protocols giving an
optimal result were all based on HIER in PT-Link using Target
Retrieval Solution pH 9 (EnVision FLEX TRS high pH), an incubation
time of 20 min in the primary Ab and EnVision Flex (K8000) or Flex+
(K8002) as the detection system. Using these protocol settings all of 13 (100 %) laboratories produced a sufficient staining.
mAb clone bcl-2/100/D5 (prod. no. PA0117, Leica): The
protocols giving an optimal result were based on HIER using Bond
Epitope Retrieval Solution 1 (Bond, Leica), an incubation time of 25
or 30 min in the primary Ab and BOND Polymer Refine Detection
(DS9800) as the detection system. Using these protocol settings both
of 2 laboratories produced an optimal staining.
The most frequent causes of insufficient staining reactions were:
- Too low concentration of the primary antibody
- Less successful RTU mAb clone 124 (Ventana/Cell Marque, see table
1)
- Too low protocol sensitivity for mAb clone 124 stained on the
Ventana BenchMark XT or Ultra platform.
In this assessment and in concordance to the previous assessment of
Bcl-2, run 13 2005, the prevalent feature of an insufficient staining
was a too weak or false negative staining. This pattern was seen in
both the normal peripheral B- and T-cells in the tonsils and the
appendix, but also in the neoplastic cells of the two follicular
lymphomas and especially in the neoplastic cells of the lymphoma
grade III. The mAb clone 124 was the most commonly used marker for
Bcl-2. The staining result seemed to be influenced by the automation platform
used for the staining. When clone 124 was used on a Ventana
BenchMark or Ultra only 21 out of 42 (50%) of the protocols gave a sufficient
staining, and only 4 protocols resulted in an optimal staining. The
protocols giving an optimal result were typically based on a high
concentration of the clone (1:10 – 1:20), efficient HIER by Standard CC1, and UltraView + amplification as the detection system. No optimal
results were obtained when the clone was applied as a RTU format (Ventana/Cell Marque). When the same clone was used
on,
e.g., the Dako Autostainer platform 59 out of 61 (97%) of the protocols gave a sufficient result.
The mAb could both be used as a
concentrate, typically diluted in the range of 1:50 – 400, and in an
RTU format.
Tonsil appeared to be a
suitable control: In the optimally calibrated protocols the majority
of the basal squamous epithelial showed a weak to moderate but
distinct cytoplasmic staining, indicating that these cells may serve
as a reliable positive critical stain quality indicator (CSQI) for
Bcl-2.
This was the 2nd assessment of Bcl-2 in NordiQC, as Bcl-2 also was
assessed in run 13, 2005 (Table 2). The
lower pass rate in the current run is probably due to more challenging tissue material
circulated, a significant increase in the number of new
participants, and a larger
number of laboratories using clone 124 with a Ventana system.
Table 2:
Proportion of sufficient results for Bcl-2 in the two NordiQC runs
performed
| |
Run
13 2005 |
Run 28 2010 |
|
Participants, n= |
87 |
155 |
|
Sufficient results |
93 % |
82 % |
Conclusion
The mAbs clones 124, 100, 100/D5, bcl-2/100/D5 and 3.1 can all be
used to obtain an optimal staining of Bcl-2. For all 5 mAbs
HIER is mandatory to obtain an optimal staining. The concentration
of the mAb clone 124 is highly dependant of the stainer applied. Tonsil is an appropriate control: An at least
weak but distinct cytoplasmic reaction must be seen in the majority
of the basal squamous epithelial cells, while the germinal centre
B-cells should be negative.
|